Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Mentara Therapeutics
Acquired Company
Eumentis Therapeutics, Inc.
Madhya Pradesh
NewtonBiotechnologyHealth CareTherapeuticsHealthcareDescription
Mentara Therapeutics has officially launched following the acquisition of MTA-304 from EuMentis Therapeutics. MTA-304 is a Phase 2-ready PDE10A inhibitor aimed at treating levodopa-induced dyskinesia in Parkinson's disease. This acquisition allows EuMentis shareholders to become part of Mentara. Financial terms of the deal were not disclosed.
Fundz sees it the moment Mentara Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Eumentis Therapeutics, Inc.?
Eumentis Therapeutics, Inc. was acquired by Mentara Therapeutics, based in Madhya Pradesh. The deal was reported on October 7, 2026. Mentara Therapeutics is a neuropsychiatry company focused on advancing treatments for Parkinson’s disease. The company has launched with the acquisition of MTA-304, a Phase 2-ready PDE10A inhibitor. Mentara Therapeutics is privately held and operates in Biotechnology.
When did Mentara Therapeutics acquire Eumentis Therapeutics, Inc.?
Mentara Therapeutics's acquisition of Eumentis Therapeutics, Inc. was reported on October 7, 2026. Mentara Therapeutics has officially launched following the acquisition of MTA-304 from EuMentis Therapeutics. MTA-304 is a Phase 2-ready PDE10A inhibitor aimed at treating levodopa-induced dyskinesia in Parkinson's disease. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Eumentis Therapeutics, Inc. do?
EuMentis Therapeutics Inc. is a privately held clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat neuropsychiatric conditions with high unmet need. It is privately held, operating in Healthcare, and is based in Newton.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.